Urinary neopterin in patients with upper gastrointestinal, biliary and pancreatic carcinomas

Pteridines

Volumn 17, Issue 1, 2006, Pages 20-24

  Melichar, Bohuslav ^a   Solichová, Dagmar ^a   Svobodová, Iveta ^a   Urbánek, Lubor ^a   Melicharová, Karolina ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cholangiocarcinoma; Gallbladder carcinoma; Gastric carcinoma; Neopterin; Pancreatic carcinoma

Indexed keywords

NEOPTERIN;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CONTROLLED STUDY; FEMALE; FOLLOW UP; GALLBLADDER CARCINOMA; GASTROINTESTINAL CARCINOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PANCREAS CARCINOMA; PRIORITY JOURNAL; SURVIVAL; UNIVARIATE ANALYSIS;

EID: 33645986661     PISSN: 09334807     EISSN: 21954720     Source Type: Journal    
DOI: 10.1515/pteridines.2006.17.1.20     Document Type: Article

References (24)

1. Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner ER. Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application. Adv Clin Chem 1989; 27:81-141.
2. Reibnegger G, Fuchs D, Fuith LC, et al. Neopterin as a marker for activated cell-mediated immunity: application in malignant disease. Cancer Detect Prev 1991; 15:483-490.
3. Melichar B, Jandik P, Solichova D, et al. Urinary neopterin excretion in colorectal cancer. Onkologie 1994; 17:434-436.
4. Allen-Mersh TG, Glover C, Fordy C, Henderson DC, Davies M. Relation between depression and circulating immune products in patients with advanced colorectal cancer. J Roy Soc Med 1998; 9:408-413.
5. Weiss G, Kronberger P, Conrad F, Bodner E, Wachter H, Reibnegger G. Neopterin and prognosis in patients with adenocarcinoma of the colon. Cancer Res 1993; 53:260-265.
6. Conrad F, Bodner E, Fuchs D, et al. Determination of neopterin - a marker of cellular immunity - in gastrointestinal and pancreatic carcinoma. In: Pfleiderer W, Wachter H, Curtius C, eds. Biochemical and Clinical Aspects of Pteridines. Berlin-New York: Walter de Gruyter 1984; 357-366.
7. Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C. Cancer mortality in Europe, 1990-1994, and an overview of trends from 1955 to 1994. Eur J Cancer 1999; 35:1477-1516.
8. Cermanová M, Melichar B, Solichová D, Bláha M, Bláha V, Blazek M, Mašín V, Cerman J, Zadák Z. Urinary neopterin and microalbuminuria in patients treated by low-density lipoprotein apheresis. Pteridines 2005; 16:174-183.
9. Solichova D, Melichar B, Blaha V, et al. Biochemical profile and survival in nonagenarians. Clin Biochem 2001; 34:563-569.
10. Melichar B, Solichova D, Svobodova I, Melicharova K. Neopterin in renal cell carcinoma: inhalational administration of interleukin-2 is not accompanied by a rise of urinary neopterin. Luminescence 2005; 20:311-314.
11. Huber C, Batchelor JR, Fuchs D, et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-γ. J Exp Med 1984; 160:310-316.
12. Fuchs D, Hausen A, Reibnegger G, Werner ER, Dierich MP, Wachter H. Neopterin as a marker for activated cell mediated immunity: application in HIV infection. Immunol Today 1988; 9:150-155.
13. Werner ER, Werner-Felmayer G, Fuchs D, et al. Tetrahydrobiopterin biosynthetic activities in human macrophages, fibroblasts, THP-1, and T24 cell. J Biol Chem 1990; 265:3189-3192.
14. Huang A, Fuchs D, Widner B, Glover C, Henderson DC, Allen-Mersh TG. Serum trytophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer 2002; 86:1691-1696.
15. Tsuda Y, Fukuda A, Kobayashi H, et al. Serum neopterin as a marker for screening of hepatocellular carcinoma. Pteridines 2004; 15:161-169.
16. Kawasaki H, Watanabe H, Yamada S, Watanabe K, Suyama A. Prognostic significance of urinary neopterin levels in patients with hepatocellular carcinoma. Tohoku J Exp Med 1988; 155:311-318.
17. Manes G, Spada OA, Rabitti PG, et al. Neopterin serum levels in pancreatic adenocarcinoma. Int J Pancreatol 1999; 25:31-37.
18. Birk D, Gansauge F, Gansauge S, Schwarz A, Beger HG. Levels of serum neopterin are increased in pancreatic cancer patients and correlate with the prognosis. Eur J Med Res 1999; 4:156-160.
19. Peters KM, Bornhofen B, Grundmann R, et al. Neopterin als Marker einer unspezifischen Immunstimulation mittels Propionibacterium avidum KP-40 bei Patienten mit gastrointestinalen Tumoren. Med Klin 1990; 85:421-424.
20. Glimelius B, Hoffman K, Sjoden PO, et al. Chemotherapy improves survival and quality of live in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7:593-600.
21. Khan SA, Davidson BR, Goldin R, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002; 51: V11-V19.
22. Fuchs D, Hausen A, Reibnegger G, et al. Immune activation and the anaemia associated with chronic inflammatory disorders. Eur J Haematol 1991; 46:65-70.
23. Denz H, Fuchs D, Huber H, et al. Correlation between neopterin, interferon-gamma and haemoglobin in patients with haematological disorders. Eur J Haematol 1990; 44:186-189.
24. Wachter H, Artner-Dworzak E, Fuchs D, et al. Association between neopterin and iron metabolism in cancer patients. Tumor Diagn Ther 1990; 11:229-232.